Kite Pharma Inc (KITE) to Release Quarterly Earnings on Tuesday
Kite Pharma Inc (NASDAQ:KITE) will announce its earnings results before the market opens on Tuesday, November 7th. Analysts expect the company to announce earnings of ($2.14) per share for the quarter.
Kite Pharma (NASDAQ:KITE) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.97) by $0.03. The business had revenue of $10.10 million for the quarter, compared to analyst estimates of $9.59 million. Kite Pharma had a negative net margin of 1,092.54% and a negative return on equity of 59.15%. The company’s revenue for the quarter was up 110.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.91) earnings per share. On average, analysts expect Kite Pharma to post $-8.24 EPS for the current fiscal year and $-6.56 EPS for the next fiscal year.
Kite Pharma Inc (NASDAQ:KITE) opened at 179.79 on Tuesday. The stock’s 50 day moving average is $179.28 and its 200-day moving average is $117.40. Kite Pharma Inc has a 12 month low of $39.82 and a 12 month high of $179.95. The stock’s market capitalization is $10.28 billion.
TRADEMARK VIOLATION WARNING: “Kite Pharma Inc (KITE) to Release Quarterly Earnings on Tuesday” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/31/kite-pharma-inc-kite-to-release-quarterly-earnings-on-tuesday.html.
In related news, EVP Timothy L. Moore sold 6,000 shares of the stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $110.06, for a total value of $660,360.00. Following the completion of the sale, the executive vice president now directly owns 55,400 shares of the company’s stock, valued at approximately $6,097,324. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Paul L. Jenkinson sold 948 shares of the stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $179.66, for a total value of $170,317.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 156,136 shares of company stock valued at $21,572,387. Company insiders own 14.00% of the company’s stock.
Several equities research analysts recently issued reports on KITE shares. Canaccord Genuity set a $115.00 price target on Kite Pharma and gave the company a “buy” rating in a research report on Monday, July 10th. Vetr upgraded Kite Pharma from a “strong sell” rating to a “strong-buy” rating and set a $116.82 price objective for the company in a research note on Monday, July 17th. Roth Capital restated a “buy” rating and set a $93.00 price objective on shares of Kite Pharma in a research note on Tuesday, July 4th. Jefferies Group LLC upped their price objective on Kite Pharma from $101.00 to $121.00 and gave the stock a “buy” rating in a research note on Monday, July 10th. Finally, Wedbush upgraded Kite Pharma from an “underperform” rating to a “neutral” rating in a research note on Tuesday, August 29th. Thirteen analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $94.68.
Kite Pharma Company Profile
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Receive News & Ratings for Kite Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.